News
The partnership also includes a license for NextCure to access Simcere Zaiming’s proprietary linker and TOPOi payload for a preclinical-stage novel target ADC developed by NextCure. Simcere Zaiming ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback